Sclerostin Levels Associated with Inhibition of the Wnt/β-Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus | Zendy

Agostino Gaudio | Zendy; Filippo Privitera | Zendy; Katia Battaglia | Zendy; Venerando Torrisi | Zendy; Maria Helga Sidoti | Zendy; Ivana Pulvirenti | Zendy; Elena Canzonieri | Zendy; Giovanni Tringali | Zendy; Carmelo Erio Fiore | Zendy

Open Access

Sclerostin Levels Associated with Inhibition of the Wnt/β-Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus

Author(s) -

Agostino Gaudio,

Filippo Privitera,

Katia Battaglia,

Venerando Torrisi,

Maria Helga Sidoti,

Ivana Pulvirenti,

Elena Canzonieri,

Giovanni Tringali,

Carmelo Erio Fiore

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-1901

Subject(s) - sclerostin , endocrinology , medicine , bone remodeling , n terminal telopeptide , type 2 diabetes mellitus , bone mineral , alkaline phosphatase , wnt signaling pathway , diabetes mellitus , chemistry , osteocalcin , osteoporosis , signal transduction , enzyme , biochemistry

Patients with type 2 diabetes (T2DM) have low bone turnover, poor bone quality, and circulating levels of sclerostin significantly higher than non-T2DM controls. There are no data on the possible association of sclerostin with β-catenin, a key component of the Wnt/β-catenin canonical signaling.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research